Mexican Council of Ophthalmology stated that a person with diabetes takes 5-15 years to develop this complication, as per the care and clinical control they maintain. However, in half the cases there is delay in diagnosis by the general practitioner.

Diabetic retinopathy is the third leading cause of irreversible blindness in the world. It is characterized by a gradual loss of vision due to the deterioration caused in the blood vessels of the retina by the elevated levels of glucose. This disease “is not very well known” by the first level doctors responsible for providing care and follow-up to diabetic patients, especially those who attend public institutions.

Reviews every six months prevents complications such as the formation of macular edema, which causes irreversible blindness. Although retinopathy is not curable, its progression can be reversed by an injection of antiangiogenic drugs, which regulate the formation of blood vessels within the eye.

According to the International Agency for the Prevention of Blindness (IAPB) for Latin America, Mexico has a high prevalence of diabetes but lacks awareness and sufficient services. The International Diabetes Federation and the International Federation on Old Age, surveyed patients with diabetes and retinopathy in Mexico and found that almost 20% never talked to their doctor about eye complications and 28% did so once symptoms appeared.

In addition, 43% of diabetic patients surveyed did not believe that their disease is well controlled and are four times more concerned about vision loss than about cardiovascular diseases that diabetes can bring. The results of the study reveal a lag in ophthalmological care for patients with diabetes, for not only those who live in cities but those in the most remote rural areas.

Noticiassin

Mexico, Brazil and Argentina currently account for 67% of mobiles apps focused on providing health care options. And to improve the application of information technologies in health, access could be given to 15.5 million additional patients per year in Mexico.

The saturation of the public health system in Mexico has forced the private sector to innovate the techniques of care for patients who have a high possibility of being incapacitated.

The company Group Sohin launched the Concierge app, currently used by more than 4,000 patients, which functions as a digital complement that provides personalized attention to patients with complex chronic-degenerative diseases.

With this application, the company assigns a person who supports the patient to complete the administrative procedures and accompanies him in their treatments, in addition allows him to share his mood to receive emotional support in his recovery.

20minutos

Chronic allergy can last up to three months and in many cases, is recurrent despite the treatments that the patient has undergone. The INER observed that prevalence of allergies in Latin America particularly in Mexico is similar to the numbers reported in highly industrialized countries.

For some types of allergies, the numbers in Mexico is slightly above the global average. According to research in Ciudad Victoria, Tijuana, Mexicali and Monterrey, rhinitis affects 27% of the children between six to seven years and 43% of adolescents aged 13-14years. The category of antihistamines to treat allergies in Mexico reports sales of USD42.2 million and three million units each year.

Unimexicali

The NIH forms a very prominent part of health system and provide services with high quality services for free. Mexico occupies the 29^th position in scientific production globally and second in Latin America. UNAM is the most important academic center of the country with 4,598 researchers in the National System of Researchers (SNI), followed by the CONACYT research centers with 1,661.

The NIH and the Hospitals of High Specialty have 1,188 SNI researchers. The formation of the “National Consortium for Research and Innovation in Translational Medicine” will allow a greater involvement of UNAM, CONACYT and the health sector to move from basic research to clinical applications and technological developments.

Inter-institutional cooperation becomes the backbone of this consortium. Transnational medicine was defined as medicine/technology where one can transfer from one place to another. The NIH will be conducting most of the clinical research and teaching supported by UNAM and CONACYT.

The consortium will also be supported by trusts, foundations and companies. Within this framework, awards were given to 10 distinguished researchers from the health system.